Rationale and study design of a cross sectional study documenting the prevalence of Heart Failure amongst the minority ethnic communities in the UK: the E-ECHOES Study (Ethnic - Echocardiographic Heart of England Screening Study) by Gill, PS et al.
BioMed CentralBMC Cardiovascular Disorders
ssOpen AcceStudy protocol
Rationale and study design of a cross sectional study documenting 
the prevalence of Heart Failure amongst the minority ethnic 
communities in the UK: the E-ECHOES Study (Ethnic - 
Echocardiographic Heart of England Screening Study)
Paramjit S Gill*1, Russell Davis2, Michael Davies3, Nick Freemantle1 and 
Gregory YH Lip2
Address: 1Primary Care Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK, 2University Department of Medicine, 
City Hospital, Birmingham, B18 7QH, UK and 3University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, B15 2TH, UK
Email: Paramjit S Gill* - p.s.gill@bham.ac.uk; Russell Davis - russell.davis@swbh.nhs.uk; Michael Davies - Michael.davies@uhb.nhs.uk; 
Nick Freemantle - n.freemantle@bham.ac.uk; Gregory YH Lip - g.y.h.lip@bham.ac.uk
* Corresponding author    
Abstract
Background: Heart failure is an important cause of cardiovascular morbidity and mortality.
Studies to date have not established the prevalence heart failure amongst the minority ethnic
community in the UK. T'he aim of the E-ECHOES (Ethnic - Echocardiographic Heart of England
Screening Study)is to establish, for the first time, the community prevalence and severity of left
ventricular systolic dysfunction (LVSD) and heart failure amongst the South Asian and Black
African-Caribbean ethnic groups in the UK.
Methods/Design: This is a community based cross-sectional population survey of a sample of
South Asian (i.e. those originating from India, Pakistan, Bangladesh) and Black African-Caribbean
male and female subjects aged 45 years and over. Data collection undertaken using a standardised
protocol comprising a questionnaire incorporating targeted clinical history taking, physical
examination, and investigations with resting electrocardiography and echocardiography; and blood
sampling with consent. This is the largest study on heart failure amongst these ethnic groups. Full
data collection started in September 2006 and will be completed by August 2009.
Discussion: The E-ECHOES study will enable the planning and delivery of clinically and cost-
effective treatment of this common and debilitating condition within these communities. In addition
it will increase knowledge of the aetiology and management of heart failure within minority ethnic
communities.
Background
Heart failure (HF) is an increasing cause of cardiovascular
morbidity and mortality within the western world. It is
important because it is common, costly, disabling and
deadly. Further, it is also treatable. Nonetheless, the
majority of data on the clinical epidemiology, prognosis
and management strategies for heart failure have been
derived predominantly from the white population. There
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[1-3]
Heart failure is a disabling condition, reducing self-
reported quality of life more than most other chronic
medical conditions. [4,5]; as well as being a major cause
of healthcare expenditure. A recent estimate was that HF
directly accounted for 1.9% of total NHS spending in the
UK, with 69% of this being on hospitalisations, and indi-
rectly (via long-term nursing care costs and secondary
admissions) for a further equivalent of 2.0% of NHS
expenditure. [6] Surveys in the UK and elsewhere show
that 1-2% of the population as a whole and 10-20% of the
very elderly have heart failure. [7,8] A large primary care
based study in the West Midlands, the ECHOES study,
found that prevalence of definite or probable heart failure
in a predominantly White population aged 45 and older
was 3.1%. [9] The increasing numbers of elderly will
almost certainly mean there will be a further increase in
the prevalence (and incidence) of heart failure over the
next 20 years. [10] The symptoms and prognosis of
patients with overt HF due to left ventricular systolic dys-
function (LVSD) are improved significantly by angi-
otensin converting enzyme inhibitors [11] and beta-
blockers [12,13]; and ACE inhibitors in patients with
asymptomatic LVSD can also delay or prevent progression
to symptomatic heart failure [14,15]. Recent evidence sug-
gests that different ethnic groups may respond differently
to these therapies. [1,16] Finally, HF has a very high mor-
tality, at around 80% in men within six years of diagnosis
[17], a prognosis worse than most forms of cancer.
Black minority ethnic groups in the United Kingdom
There were 4.6 million people (7.9%) from the Black and
minority ethnic groups in the 2001 Census. The Black,
Indian, Pakistani and Bangladeshi groups comprised 2%,
1.8%, 1.3%, 0.5% respectively. [18] The majority reside in
large metropolitan areas and Birmingham has the largest
proportion outside London.
Cardiovascular morbidity and mortality are substantially
higher amongst these groups than the White population.
[18] South Asians (SAs) living in the UK (i.e. those origi-
nating from India, Bangladesh or Pakistan), have a 50%
greater risk of dying prematurely from coronary heart dis-
ease than the general population.[18] In contrast, prema-
ture death rates from CHD for Caribbeans and West
Africans are much lower than average - around half the
rate found in the general population for men and two-
thirds of the rate found in women - despite the fact that
hypertension is much commoner amongst these groups.
Another major risk factor for HF is diabetes mellitus,
which is much more common in African-Caribbean and
South Asian minority groups than in the population as a
whole.
Importantly, the difference in the death rates between SAs
and the rest of the population is increasing. This is
because the death rate from CHD is not falling as fast in
SAs as it is in the rest of the population. From 1971 to
1991, the mortality rate for 20-69 year olds for the whole
population fell by 29% for men and 17% for women,
whereas in SAs it fell by 20% for men and 7% for women.
[19] As myocardial ischaemia/infarction is the common-
est cause of LVSD which is the most important and serious
functional abnormality in patients with HF, it is to be
expected that the prevalence of HF would be much higher
in SAs.
Heart failure in Black African-Caribbean and South Asians 
in the UK
The prevalence of HF in the SAs is currently not known as
these groups have generally been underrepresented in pre-
vious studies. [1,9,20] Indeed, we are not aware of any
population based epidemiological studies amongst these
populations in the UK or other countries.
As is the case in African-Americans, HF occurs at an earlier
age in SAs than in the White community. [21-26]
Although no prospective data exist, a reanalysis of the data
from our own study of acute HF admissions to a UK city
centre hospital [21] has suggested that the relative risk of
HF in those aged 60-79 years was 3.1 (95% CI 1.9-4.9) for
African-Caribbean, and 5.2 (95% CI 3.7-7.4) for SAs. At 8
years' follow-up, the total mortality was 90.5% amongst
whites and 87.0% amongst non-whites (Log Rank test, p
= 0.07) where the non-white patients had numerically
better survival at all time points until 6 years, after which
the survival curves started to converge. [27] However,
since African-Caribbean and SA patients were younger
than their white counterparts, age at death appeared
younger in these groups.
In addition to methodological issues with these studies
conducted in secondary care, they have also focussed on
particular ethnic groups and analysis have been reported
by aggregating the groups, thereby masking the differ-
ences that may exist between the groups, particularly the
SA category. [28,29] Indeed, we recognise that there are
known differences in the subgroups (i.e. Indian, Paki-
stani, Bangladeshi) within the SA category. [30] Therefore,
a primary care based study to determine the prevalence of
LVSD and the syndrome of HF in this ethnic group is
needed. Several of the investigators in this study were
involved in the ECHOES study [9], in which the large
majority of subjects studied were white.
Primary Objective
To establish the community prevalence and severity of
LVSD and heart failure [31] amongst the South AsianPage 2 of 7
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bean ethnic groups in the UK.
Methods/Design
Ethical approval
The Walsall Local Research Ethics Committee has
reviewed and approved the protocol (05/Q2708/45). Ver-
bal and written consent will be obtained.
Recruitment
This is a cross-sectional population survey of a sample of
SA and Black African-Caribbean male and female resi-
dents of Birmingham aged 45 years and over. Recruitment
entails a two-staged process with initial sample of general
practices known to have high proportion of these minor-
ity ethnic patients and then a sample using the patient
age-sex register.
Using 2001 Census data wards, serving the Birmingham
Special Health Authority area, having >5% SAs and/or
Black African-Caribbean as residents will be selected and
general practices recruited from these wards.
From the practice age-sex registers, all eligible subjects will
be selected by sex and aged 45 years and over. As well as
making the study directly comparable to ECHOES [9], it is
also important to include those aged 45 and over in view
of the earlier onset of ischaemic heart disease in SAs [18],
which could result in a significant prevalence of HF in
those aged 45-54 years. Subjects in the high-risk groups
(i.e. hypertension, diabetes mellitus, ischaemic heart dis-
ease) will also be included, but not 'singled out' prospec-
tively. Some of the general practices record ethnic group,
but as ethnic group collection is not mandatory in pri-
mary care [32], we will use a combination of methods to
identify the subjects. For SAs, we will screen the list for SA
names using the Nam Pechan software that has been
shown to be valid [33]; and for Black African-Caribbean
subjects we will consult practice staff (see Figure 1). The
general practitioner will then review the lists to ensure
that only SA and Black African-Caribbean subjects are
included and exclude any whom they consider it inappro-
priate to approach; for example, due to terminal illness or
dementia. Finally, all eligible subjects will be asked their
ethnic group before booking an appointment.
For pragmatic reasons, all eligible subjects will be invited
for screening from each practice as minority ethnic groups
tend to register with a specific practice in each area so that
with random sampling, we would have to recruit not only
a larger number of practices but these will also be dis-
persed over a number of health authority areas. This will
lead to co-ordination and recruitment difficulties.
To facilitate recruitment, publicity in local media and con-
sultation with community leaders will be undertaken, in
addition to letters of invitation (in the appropriate lan-
guages) being sent to each potential subject inviting them
to attend their practice. Further, we plan for interpreting
provision and using the Health Survey for England 1999
[34] anticipate that 20% of the subjects will need inter-
preting due to poor spoken English.
Baseline assessment of subjects
Subjects invited to attend for an assessment at their local
general practice. At the clinic, the Research Fellow and
Research Associate collected data by interview-adminis-
tered questionnaire, undertook a physical examination,
and performed an ECG and echocardiogram.
The Questionnaire includes the following data: age; date
of birth; address; post code; self-determined ethnicity;
religion; place of birth; migration history; languages spo-
ken; level of education; alcohol consumption; cigarette
smoking including other tobacco use; exercise assessment;
history of illness in self and family; current medication;
dyspnoea scoring leading to New York Heart Association
functional classification All these measures are based on
existing surveys such as the Health Survey for England
[34] and the Fourth National Survey of Ethnic Minorities
in Britain. [35] Information on co-morbidity (myocardial
infarction, angina, hypertension, heart failure, stroke, dia-
Flow of participants through studyigure 1
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ing the general practitioner notes.
At physical examination, the following measurements
will be undertaken using standard procedures: Height,
weight, body mass index, resting pulse, systolic and
diastolic blood pressure using an automated sphygmoma-
nometer, and waist measurement. The height of the JVP
will assessed; the heart auscultated for murmurs and
added sounds, and the chest examined for signs of conges-
tion and other abnormalities. Hepatomegaly, ascites and
peripheral oedema will also be searched for. A resting 12
lead ECG (Mortara ELI 150) will be recorded, and coded
independently by two cardiologists using the Minnesota
criteria. [36]
Echocardiography will performed within the general prac-
tice surgeries by trained research fellows. This will be done
using a portable VIVID i machine (GE Healthcare, Chal-
font St Giles, UK), which produces good image quality
and has tissue harmonic imaging capability and high
quality colour and spectral Doppler facilities. Chamber
dimensions will be obtained from the parasternal win-
dows, and the presence and degree of left ventricular
hypertrophy noted. Left ventricular function will be meas-
ured objectively using an area-length method from the
apical four-chamber view. In cases where an objective
measurement of left ventricular ejection fraction is not
possible, a qualitative assessment will be made, that is,
definite impairment (LVEF <40%), borderline (40-50%)
and preserved (>50%), consistent with the investigators'
normal clinical practice. Valve disease will be assessed
semi-quantitatively and recorded, along with any other
abnormalities. Parameters of diastolic function (mitral
valve E:A ratio; E wave deceleration time; and isovolumic
relaxation time) will also be measured. Tissue Doppler
studies of the motion of the mitral valve annulus will also
provide further insights into diastolic function.
HF will be defined using explicit criteria following the
European Society of Cardiology (ESC) guidelines,[31]
taking into account both symptomatic status and objec-
tive functional abnormalities on echocardiography.
A random blood sample will be obtained from those con-
senting by atraumatic venepuncture and stored at 4°C for
up to 4 hours before transportation to the central labora-
tory for storage at -70°C for batch analysis. Initial analyses
include renal function and lipids using routine automated
methodology using reagents from Roche Diagnostics
within a clinical Biochemistry laboratory (Lewes, UK).
Similarly, HbA1c was measured using semi-automated
HPLC methodology (Menarini, Berkshire, UK). As
patients will be non-fasting, plasma triglyceride levels not
measured. BNP measured using an established automated
immunoassay technique using a commercially available
assay (ADVIA Centaur, Bayer Healthcare, Newbury, UK).
In addition, a full blood count will be tested. We will also
store DNA at -70°C for future genetic analysis.
All subjects will be followed for long term outcomes.
Quality control measures
The research team will be provided with training at the
start of the project on administering the questionnaire;
performing physical examination, the ECG and echocar-
diogram. The research team will follow written standard
operating procedures that include a number of quality
control checks, including re-reporting by a senior cardiol-
ogist of all abnormal echocardiograms and a sample of
those reported by the research fellow as normal. As stated
above, we will follow the same methodology as in the
ECHOES study [9] and ensure between study quality con-
trol as 2 of the assessors (RCD, MKD) were also investiga-
tors in the ECHOES study.
Feedback to informants
Each subject will be asked if they want their results to be
forwarded to their GP. Written consent will be obtained
for this. If any study results gave cause for concern, sub-
jects will be asked to make an appointment with their GP.
Sample Size and Statistical Analysis
Response rate
It is stated that response to surveys by minority ethnic
groups are low but this is not borne out by the extensive
study by Bhopal et al [28] who achieved a 68% response
rate. In the Health Survey for England [34], the response
rate was over 80% in all six ethnic groups for interview,
although this fell to below 50% for blood sampling. Our
conservative estimate is a response of 50%, although every
effort will be made to achieve a high response rate. In the
predominantly white population studied in ECHOES [9],
a 62.9% response rate was achieved by the investigators.
Non-responders will be contacted by telephone where
possible, and by a second letter of invitation.
Principal Question - Prevalence of heart failure in SA 
population
The principal question addressed in this study is to esti-
mate the prevalence of HF in the SA population. The pre-
cision of estimation of prevalence is dependent upon the
number of subjects and the prevalence rate. Given the
sample size of 3000 subjects, the 95% confidence inter-
vals around a prevalence estimate of 2.3% will be ± 0.5%.
Because of the properties of the binomial distribution, the
width of confidence intervals will increase with increasing
prevalence of heart failure within the plausible range of
values (e.g. to 50% prevalence). Thus, with a prevalence of
heart failure of 5%, the 95% confidence intervals will be ±
0.8%, and for 10% prevalence they will be ± 1.1%.Page 4 of 7
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This comparison will be undertaken making comparison
with the rate of heart failure identified in the ECHOES
study.[9] For this comparison, the study as planned will
be have statistical power (1-) of 80% to find a 1.3% dif-
ference in prevalence of heart failure as statistically signif-
icant at the conventional 2 sided  of .05. Similarly the
study will have 90% power (1-) of 90% to find a differ-
ence of 1.5% statistically significant.
Further we will describe the prevalence of heart failure in
each of 3 SA population subgroups. In each subgroup,
1000 subjects will be recruited. The 95% confidence inter-
vals around the estimate of prevalence for each subgroup
would be ± 1.0% for a prevalence rate of 2.8%, ± 1.4% for
a 5% prevalence, and ± 1.9% for a prevalence of 10%.
While our principal aims in this study are to provide reli-
able estimates of the prevalence of HF in the broad SA
group and subgroups, we will also be in a position to
compare explicitly the rates of heart failure in different
groups. The statistical power for different comparisons
depends upon the reference group rate, and this is
described in the table below for different levels of statisti-
cal power (1-) and for different comparator or reference
group rates).
Principal Question - Prevalence of heart failure in AC 
population
With a given 2% prevalence rate amongst the white popu-
lation in ECHOES, we can make some direct contrast with
that population. If we recruit 2000 patients in E-ECHOES
AC, we have 90% power (1-beta) to find a 1.5% absolute
difference in prevalence of heart failure between the two
studies as statistically significant at the standard alpha
level (two sided) of 5%. Further, within the proposed
study, we have 90% power to find statistically significant
differences of around 2.25%, given the range of compara-
tor group sizes and of prevalence rates. Table 1
Analysis Plan
Descriptive analyses will be performed on all study varia-
bles, describing rates as percentages, and continuous vari-
ables as medians and lower and upper quartiles. Observed
proportions of interest (notably heart failure prevalence
estimates) will be described with 95% confidence inter-
vals. For the comparisons of heart failure rates by survey,
an exact test and confidence interval will be used to
describe the estimated differences between the groups. In
addition, a further exploratory multivariable binomial
mixed analysis will be conducted using individual subject
data from both studies, making appropriate adjustment
for age, sex and practice (as a random effect).
Discussion
The E-ECHOES study will be the largest community study
documenting for the first time community prevalence of
left ventricular systolic dysfunction and heart failure
amongst the South Asian and Black African-Caribbean
ethnic communities. It will provide pre-existing co-mor-
bidity data; and follow-up will enable survival from heart
failure amongst these communities.
It will provide the evidence base for the planning and
management of this common disabling condition within
the community.
Table 1: Statistical power for different comparisons between subgroups
Comparator Rate (n = 1000) 80% power (1-) (n = 1000) to find the following 
difference significant at  = .05
90% power (1-) (n = 1000) to find the following 
difference significant at  = .05
3% 2.5% 3.0%
4% 2.8% 3.4%
5% 3.0% 3.6%
6% 3.3% 3.9%
7% 3.5% 4.1%
8% 3.7% 4.4%
9% 3.9% 4.6%
10% 4.1% 4.8%Page 5 of 7
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